01 / Contract Profile
75A50123C00060 Federal Contract Award
Agency code 7505
THE DEVELOPMENT OF A MULTIMODAL ANTIBODY PLATFORM TO EXTEND THE WINDOW OF IMMUNOTHERAPEUTIC INTERVENTION. THE OVERALL OBJECTIVE OF THE WORK OUTLINED IN THIS CONTRACT IS TO CRITICALLY EVALUATE THE UTILITY OF THE VHH AS A PLATFORM MCM TECHNOLOGY FOR VI
02 / Contract Size and Status
What is the recorded size and timing of this contract?
03 / Spending Trend
75A50123C00060 contract spending by fiscal year
Annual net obligations across the complete period available for this agency and PIID, from the first recorded fiscal year through the latest contract action.
Latest fiscal year obligations$1.89M
FY 2026Net obligationsComplete recorded range
| Fiscal year | Net obligations | Actions | Change |
|---|---|---|---|
| FY 2023 | $9.65M | 2 | — |
| FY 2024 | $16.96M | 1 | +75.8% |
| FY 2025 | $4.56M | 2 | −73.1% |
| FY 2026 | $1.89M | 2 | −58.5% |
04 / Federal Buyer
Which organization manages this contract?
| Department | Contracting agency | Contracting office |
|---|---|---|
| HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE | BARDA - ASPR / DAAPPO / BARDA DCMA |
05 / Contractor
Who holds this federal contract?
EITR BIOLOGICS, INC.
UEI HX49LZLY32G5 · CAGE 99JH0
06 / NAICS Industries
Which industries classify this contract?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 541714 | RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) | $33.06M | 7 | 100.0% |
07 / Products and Services
What products or services were purchased?
| Code | Description | Obligations | Actions | Share |
|---|---|---|---|---|
| 3650 | CHEMICAL AND PHARMACEUTICAL PRODUCTS MANUFACTURING MACHINERY | $33.06M | 7 | 100.0% |
08 / Place of Performance
Where is the work recorded?
SAN DIEGO, SAN DIEGO, CALIFORNIA, UNITED STATES
ZIP 921214348
09 / Contract Actions
What modifications and obligations were recorded?
| Signed date | Modification | Obligation | Contracting office | NAICS | PSC |
|---|---|---|---|---|---|
| Jul 28, 2026 | P00006 | $1.89M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| May 19, 2026 | P00005 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| Jul 15, 2025 | P00004 | $4.56M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| Jan 7, 2025 | P00003 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| Mar 19, 2024 | P00002 | $16.96M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| Dec 7, 2023 | P00001 | $0 | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
| Sep 22, 2023 | Base action | $9.65M | BARDA - ASPR / DAAPPO / BARDA DCMAOffice code 75A501 | 541714 | 3650 |
10 / Reading the Contract
How should this award record be interpreted?
Read the PIID as a transaction history, not as a single purchase price. Net obligations combine the base action with later increases, reductions, corrections, and deobligations recorded under the same contract.
Verify the buyer
Agency and office identify who manages the procurement relationship.
Follow modifications
Each action can change funding, scope, dates, or administrative terms.
Compare the market
Use NAICS, PSC, and the contractor profile to identify related buyers and competitors.